Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Dr. Lugui Qiu: Progress Flourishes with a Precision-Based Lymphoma Diagnosis and Treatment System

Lymphoma is a common malignant disease of the lymphatic system that poses a significant threat to public health. China faces a rapidly increasing burden of lymphatic tumors. The GBD 2019 study shows that China accounts for 10.8% of the world's new cases of Hodgkin lymphoma and 9.8% of the deaths, as well as 20.1% of the new cases and 17.4% of the deaths from non-Hodgkin lymphoma. Therefore, improving lymphoma diagnosis and treatment levels is a critical challenge in China. To gain a deeper understanding of the current status and progress of lymphoma diagnosis and treatment in China, Hematology Frontier interviewed Dr. Luguo Qiu, Director of the Lymphoma Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences , for an in-depth analysis of this topic.
Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO) & 4th International Congress of the Asian Oncology Society (AOS2024)

Welcome to 2024 Chinese Congress of Holistic Integrative Oncology (2024 CCHIO) & 4th International Congress of the Asian Oncology Society (AOS2024)

On behalf of the organizing committee of the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), we are very pleased to invite you to attend the 2024 CCHIO & 4th International  Congress of the Asian Oncology Society (AOS2024) . This esteemed event will be held from November 14-16, 2024, in the historic and culturally rich city of Xi'an, China, the birthplace of Holistic Integrative Medicine. The 2024 CCHIO is proudly sponsored by the China Anti-Cancer Association and co-organized by the Shaanxi Anti-Cancer Association, and the China Research Institute of Development Strategies of Holistic Integrative Medicine.
Dr. Nan Bi Discusses Advances in Radiotherapy for NSCLC in 2024 | 2024 Precision Medicine Conference on Lung Cancer

Dr. Nan Bi Discusses Advances in Radiotherapy for NSCLC in 2024 | 2024 Precision Medicine Conference on Lung Cancer

At the recently held 2024 Precision Medicine Conference on Lung Cancer, Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences, delivered a presentation titled "Advances in Radiotherapy for NSCLC in 2024." The talk covered key developments in radiotherapy combined with targeted therapy, radiotherapy combined with immunotherapy, and technological advancements in radiotherapy. In an exclusive interview with Oncology Frontier, Professor Bi further elaborated on some of the most pressing topics in this evolving field.
Dr.  Zefei Jiang ‘s Overview of Breast Cancer Research Progress in 2023

Dr.  Zefei Jiang ‘s Overview of Breast Cancer Research Progress in 2023

In 2023, significant progress has been made in the field of breast cancer research. Dr.  Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang's speeches, exploring the key advancements in breast cancer treatment in 2023.
Blood Science Update: New Insights into the Endothelial Origin of the Hematopoietic System

Blood Science Update: New Insights into the Endothelial Origin of the Hematopoietic System

This article, published in the journal Blood Science, elucidates groundbreaking advancements in understanding the endothelial origins of the hematopoietic system. As a leading platform in clinical and experimental hematology, Blood Science continues to publish high-impact research that transforms molecular biology and physiology. Authored by Professor Yu Lan from the Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University and Professor Bing Liu from the Fifth Medical Center, Chinese PLA General Hospital, this study delves into the complex cellular evolution of hemogenic endothelial cells (HECs), the molecular mechanisms driving endothelial-to-hematopoietic transition (EHT), and the striking parallels between human and mouse systems. These insights mark a significant leap toward regenerative medicine and innovative treatments for hematological disorders.
Blood Science Update: Versatility of Megakaryocytes in Health and Disease

Blood Science Update: Versatility of Megakaryocytes in Health and Disease

This article, published in the esteemed journal Blood Science, explores the remarkable adaptability of megakaryocytes (MKs) in various physiological and pathological processes. Renowned for its pioneering work in hematology, Blood Science has showcased groundbreaking insights into the dynamic roles of MKs beyond their traditional function in platelet production, offering a deeper understanding of their involvement in immune modulation, aging, and hematological diseases.
Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide treatment decisions in this patient population.
Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024

Moving Forward with Determination, Embracing a Promising Future! Dr. Xinan Sheng on Key Advances in the Treatment of Advanced Renal Cancer in 2024

In recent years, some immunotherapy approaches for renal cancer have faced setbacks, failing to meet primary endpoints. However, with ongoing advancements in targeted therapy, immunotherapy, and other treatment modalities, significant progress has been made in managing advanced renal cancer. Notably, the success of multiple large-scale Phase III trials on targeted and immunotherapy combinations has marked the beginning of a new era in first-line treatment for advanced renal cancer. In 2024, several major breakthroughs were achieved. To provide deeper insights, Oncology Frontier invited Xinan Sheng, professor at Peking University Cancer Hospital, to summarize the key research developments that may serve as valuable references for future renal cancer treatment and research.
Annual Review | Dr. Yao Zhu: Advances in Surgical Diagnosis and Treatment of Prostate Cancer in 2024

Annual Review | Dr. Yao Zhu: Advances in Surgical Diagnosis and Treatment of Prostate Cancer in 2024

As 2024 concludes, the field of minimally invasive urological surgery has made remarkable strides, particularly in prostate cancer surgery, which often serves as a testing ground for innovative surgical approaches. With the advancement of precision medicine and multidisciplinary team (MDT) management, prostate cancer surgery now extends beyond simple tumor removal, incorporating preoperative diagnostic optimization, postoperative systemic therapy, and alternative local treatment approaches. In this annual review, Dr. Yao Zhu from Fudan University Shanghai Cancer Center summarizes the key developments in prostate cancer surgery over the past year.